Myriad Genetics Inc
MYGN: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$78.10 | Mlrhb | Ghrctykq |
No-Moat Myriad Reports Weak Q3 Results; Management Updates 2022 Guidance
No-moat Myriad Genetics reported a weak third quarter, with sales declining 2% year-over-year, driven by macroeconomic headwinds and sales declining in almost all areas of the company's portfolio except for GeneSight. We have made adjustments to our near-term assumptions that reflect the current macroeconomic environment, volume, and product mix, bringing down our fair value estimate to $18.50 per share from $21.50. Given the market's negative reaction to Myriad's third-quarter results, shares still appear slightly undervalued.